Literature DB >> 23754313

Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma.

Dusten Unruh1, Kevin Turner, Ramprasad Srinivasan, Begüm Kocatürk, Xiaoyang Qi, Zhengtao Chu, Bruce J Aronow, David R Plas, Catherine A Gallo, Holger Kalthoff, Daniel Kirchhofer, Wolfram Ruf, Syed A Ahmad, Fred V Lucas, Henri H Versteeg, Vladimir Y Bogdanov.   

Abstract

Alternatively spliced tissue factor (asTF) promotes neovascularization and monocyte recruitment via integrin ligation. While asTF mRNA has been detected in some pancreatic ductal adenocarcinoma (PDAC) cell lines and increased asTF expression can promote PDAC growth in a subcutaneous model, the expression of asTF protein in bona fide PDAC lesions and/or its role in metastatic spread are yet to be ascertained. We here report that asTF protein is abundant in lesional and stromal compartments of the five studied types of carcinoma including PDAC. Analysis of 29 specimens of PDAC revealed detectable asTF in >90% of the lesions with a range of staining intensities. asTF levels in PDAC lesions positively correlated with the degree of monocyte infiltration. In an orthotopic model, asTF-overexpressing high-grade PDAC cell line Pt45P1/asTF+ produced metastases to distal lymph nodes, which stained positive for asTF. PDAC cells stimulated with and/or overexpressing asTF exhibited upregulation of genes implicated in PDAC progression and metastatic spread. Pt45P1/asTF+ cells displayed higher coagulant activity compared to Pt45P1 cells; the same effect was observed for cell-derived microparticles (MPs). Our findings demonstrate that asTF is expressed in PDAC and lymph node metastases and potentiates PDAC spread in vivo. asTF elicits global changes in gene expression likely involved in tumor progression and metastatic dissemination, and it also enhances the procoagulant potential of PDAC cells and cell-derived MPs. Thus, asTF may comprise a novel therapeutic target to treat PDAC and, possibly, its thrombotic complications.
© 2013 UICC.

Entities:  

Keywords:  alternative splicing; metastasis; molecular mechanisms of angiogenesis; pancreatic ductal adenocarcinoma; tissue factor

Mesh:

Substances:

Year:  2013        PMID: 23754313      PMCID: PMC4122306          DOI: 10.1002/ijc.28327

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

1.  Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo.

Authors:  Grace M Thomas; Laurence Panicot-Dubois; Romaric Lacroix; Françoise Dignat-George; Dominique Lombardo; Christophe Dubois
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

2.  Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model.

Authors:  Jennifer E Hobbs; Anaadriana Zakarija; Deborah L Cundiff; Jennifer A Doll; Emily Hymen; Mona Cornwell; Susan E Crawford; Na Liu; Maxim Signaevsky; Gerald A Soff
Journal:  Thromb Res       Date:  2007       Impact factor: 3.944

3.  Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis.

Authors:  Petra Goldin-Lang; Quoc-Viet Tran; Iduna Fichtner; Andreas Eisenreich; Silvio Antoniak; Karsten Schulze; Sarah E Coupland; Wolfgang Poller; Heinz-Peter Schultheiss; Ursula Rauch
Journal:  Oncol Rep       Date:  2008-07       Impact factor: 3.906

4.  Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.

Authors:  Jeffrey I Zwicker; Howard A Liebman; Donna Neuberg; Romaric Lacroix; Kenneth A Bauer; Barbara C Furie; Bruce Furie
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

5.  Alternatively spliced tissue factor induces angiogenesis through integrin ligation.

Authors:  Y W van den Berg; L G van den Hengel; H R Myers; O Ayachi; E Jordanova; W Ruf; C A Spek; P H Reitsma; V Y Bogdanov; H H Versteeg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-29       Impact factor: 11.205

6.  EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma.

Authors:  Hendrik Seeliger; Peter Camaj; Ivan Ischenko; Axel Kleespies; Enrico N De Toni; Susanne E Thieme; Helmut Blum; Gerald Assmann; Karl-Walter Jauch; Christiane J Bruns
Journal:  Mol Cancer Res       Date:  2009-02-10       Impact factor: 5.852

7.  Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein.

Authors:  Xiaoyang Qi; Zhengtao Chu; Yonatan Y Mahller; Keith F Stringer; David P Witte; Timothy P Cripe
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

8.  SR proteins ASF/SF2 and SRp55 participate in tissue factor biosynthesis in human monocytic cells.

Authors:  J G Tardos; A Eisenreich; G Deikus; D H Bechhofer; S Chandradas; U Zafar; U Rauch; V Y Bogdanov
Journal:  J Thromb Haemost       Date:  2008-03-01       Impact factor: 5.824

9.  Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer.

Authors:  Alok A Khorana; Steven A Ahrendt; Charlotte K Ryan; Charles W Francis; Ralph H Hruban; Ying Chuan Hu; Galen Hostetter; Jennifer Harvey; Mark B Taubman
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

10.  Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Authors:  Kenneth P Olive; Michael A Jacobetz; Christian J Davidson; Aarthi Gopinathan; Dominick McIntyre; Davina Honess; Basetti Madhu; Mae A Goldgraben; Meredith E Caldwell; David Allard; Kristopher K Frese; Gina Denicola; Christine Feig; Chelsea Combs; Stephen P Winter; Heather Ireland-Zecchini; Stefanie Reichelt; William J Howat; Alex Chang; Mousumi Dhara; Lifu Wang; Felix Rückert; Robert Grützmann; Christian Pilarsky; Kamel Izeradjene; Sunil R Hingorani; Pearl Huang; Susan E Davies; William Plunkett; Merrill Egorin; Ralph H Hruban; Nigel Whitebread; Karen McGovern; Julian Adams; Christine Iacobuzio-Donahue; John Griffiths; David A Tuveson
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

View more
  20 in total

1.  Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression.

Authors:  B Kocatürk; C Tieken; D Vreeken; B Ünlü; C C Engels; E M de Kruijf; P J Kuppen; P H Reitsma; V Y Bogdanov; H H Versteeg
Journal:  J Thromb Haemost       Date:  2015-07-31       Impact factor: 5.824

2.  Distinct splice variants and pathway enrichment in the cell-line models of aggressive human breast cancer subtypes.

Authors:  Rajasree Menon; Hogune Im; Emma Yue Zhang; Shiaw-Lin Wu; Rui Chen; Michael Snyder; William S Hancock; Gilbert S Omenn
Journal:  J Proteome Res       Date:  2013-11-07       Impact factor: 4.466

3.  Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine.

Authors:  Patrick M Winter; John Pearce; Zhengtao Chu; Christopher M McPherson; Ray Takigiku; Jing-Huei Lee; Xiaoyang Qi
Journal:  J Magn Reson Imaging       Date:  2014-05-06       Impact factor: 4.813

4.  Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.

Authors:  Yi Yang; Amanda Stang; Patrick G Schweickert; Nadia A Lanman; Erin N Paul; Brett P Monia; Alexey S Revenko; Joseph S Palumbo; Eric S Mullins; Bennett D Elzey; Edith M Janssen; Stephen F Konieczny; Matthew J Flick
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

Review 5.  Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis.

Authors:  Yohei Hisada; Nigel Mackman
Journal:  Semin Thromb Hemost       Date:  2019-05-16       Impact factor: 4.180

6.  Interplay between alternatively spliced Tissue Factor and full length Tissue Factor in modulating coagulant activity of endothelial cells.

Authors:  B Ünlü; V Y Bogdanov; H H Versteeg
Journal:  Thromb Res       Date:  2017-05-25       Impact factor: 3.944

7.  Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.

Authors:  Shijun Zhu; Walter Kisiel; Yang J Lu; Lars C Petersen; John M Ndungu; Terry W Moore; Ernest T Parker; Aiming Sun; Jann N Sarkaria; James P Snyder; Dennis C Liotta; Daniel J Brat; Bassel F El-Rayes; Mamoru Shoji
Journal:  J Drug Target       Date:  2014-12-16       Impact factor: 5.121

Review 8.  "Soluble Tissue Factor" in the 21st Century: Definitions, Biochemistry, and Pathophysiological Role in Thrombus Formation.

Authors:  Vladimir Y Bogdanov; Henri H Versteeg
Journal:  Semin Thromb Hemost       Date:  2015-09-26       Impact factor: 4.180

9.  Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer.

Authors:  Kombo F N'Guessan; Harold W Davis; Zhengtao Chu; Subrahmanya D Vallabhapurapu; Clayton S Lewis; Robert S Franco; Olugbenga Olowokure; Syed A Ahmad; Jen Jen Yeh; Vladimir Y Bogdanov; Xiaoyang Qi
Journal:  Mol Ther       Date:  2020-06-08       Impact factor: 11.454

10.  Pancreatic cancer: current standards, working towards a new therapeutic approach.

Authors:  Olugbenga Olowokure; Xiaoyang Qi
Journal:  Expert Rev Anticancer Ther       Date:  2014-03-13       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.